US Patent Issued to Amunix Pharmaceuticals on Sept. 30 for "Compositions targeting prostate-specific membrane antigen and methods for making and using the same" (British, American Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,494, issued on Sept. 30, was assigned to Amunix Pharmaceuticals Inc. (South San Francisco, Calif.).

"Compositions targeting prostate-specific membrane antigen and methods for making and using the same" was invented by Viktoriya Dubrovskaya (San Francisco), Eric Johansen (Oakland, Calif.), Lucas Liu (San Bruno, Calif.), Darragh MacCann (Magherfelt, Great Britain), Volker Schellenberger (Palo Alto, Calif.) and Milton To (San Lorenzo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure describes antigen-binding molecules with binding specificity to cluster of differentiation 3 T cell receptor (CD3), antigen-binding molecules with bind...